Ossi Riekkinen

​Dr. Ossi Riekkinen is the CEO and co-founder of Bone Index Ltd., a healthcare diagnostics company with game-changing point-of-care technology (Bindex®) in osteoporosis diagnostics. The overall aim of Bindex is to prevent osteoporotic fractures, improve surgical outcomes, and improve the quality of life for families in the United States. Dr. Riekkinen has exceptional knowledge in the requirements to build and launch a healthcare company from the ground up - with 1.6 million measured patients in the U.S.

In May 2020, Bone Index launched the world’s first science-based, personalized fracture prevention program, Bindex Total Bone Health TM in the U.S. The key objective of the program is to prevent the most significant risk factor of osteoporotic bone fracture – the first fracture. The program has been designed for gyms and fitness programs which provide services for the 50+ population, specifically those on Medicare to help their members reduce fractures and maintain independence and quality of life.

Dr. Riekkinen graduated from the University of Kuopio in 2008 with a PhD in medical physics focused on osteoporosis diagnostics. In Finland, he has successfully launched the world’s largest osteoporosis screening campaign with the leading Health System and the leading beverage company. In the U.S., the use rate of Bindex scans increased from zero to one million in just 18 months.

Bindex has received impressive recognitions for the company and product – they were selected “Best Nordic Start-Up Company” (Nordic Star Award 2014) and “One of the Best Medical Devices in the World” (MedGadget, Dec 2016).

Based on U.S. treatment guidelines, the annual need for osteoporosis examinations in the U.S. is 14 million. However, the current number of the examinations is only about 2.5 million due to centralized diagnostics. A cost effectiveness study completed with Bindex and Medicare statistics indicates the total annual savings to U.S. healthcare is over $3 billion when 14 million Bindex scans are completed for at-risk patients annually. Achieving 14 million Bindex scans in the U.S. is Dr. Riekkinen’s personal target goal.